Appointments: Shire, Bicycle Therapeutics, Gilead Sciences, Astellas, Alzheon, Alnylam and Amplyx
Executive Summary
2017 begins with three Novartis executives finding new roles and high-level appointments made by Shire, Bicycle Therapeutics, Gilead Science and Amplyx Pharmaceuticals.
You may also be interested in...
Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases
CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.
Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Company no longer has to worry about a US FDA advisory committee review, which the agency cancelled. Launch preparations include hiring 140 sales reps.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.